Table 2.
Diagnostic Efficiency of FR+-CTC in Lung Cancer Histopathologic Subtype.
| Characteristics |
≥8.70 FR+-CTC Units/3 mL | <8.70 FR+-CTC Units/3 mL | ||
|---|---|---|---|---|
| NO. | % | NO. | % | |
| Lung cancer (n = 197) | 153 | 77.7 | 44 | 22.3 |
| TNM stage | ||||
| I (n = 86) | 60 | 69.8 | 26 | 30.2 |
| II (n = 18) | 13 | 72.2 | 5 | 27.8 |
| III (n = 40) | 32 | 80 | 8 | 20 |
| I+II+III (n = 144) | 105 | 72.9 | 39 | 27.1 |
| IV (n = 53) | 48 | 90.6 | 5 | 9.4 |
| Histopathologic subtype | ||||
| NSCLC (n = 162) | 125 | 77.2 | 37 | 22.8 |
| ADC (n = 115) | 88 | 76.5 | 27 | 23.5 |
| SCC (n = 28) | 20 | 71.4 | 8 | 28.6 |
| Others of NSCLC (n = 19) | 17 | 89.5 | 2 | 10.5 |
| SCLC (n = 26) | 21 | 80.8 | 5 | 19.2 |
| Others of lung cancer (n = 9) | 7 | 77.8 | 2 | 22.2 |
| Benign diseases (n = 119) | 14 | 11.8 | 105 | 88.2 |
| Healthy donors (n = 52) | 4 | 7.7 | 48 | 92.3 |